
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6972153/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic factors of health care–associated bloodstream infection in adult patients ≥40 years of age. American Journal of Infection Control, 2018, 46, 111-114.	2.3	8
2	Addressing Loss of Efficiency Due to Misclassification Error in Enriched Clinical Trials for the Evaluation of Targeted Therapies Based on the Cox Proportional Hazards Model. PLoS ONE, 2016, 11, e0153525.	2.5	0
3	Association of quality of life with laboratory measurements and lifestyle factors in community dwelling older people in Taiwan. Aging and Mental Health, 2015, 19, 548-559.	2.8	7
4	Sample Size Determination for Individual Bioequivalence Inference. PLoS ONE, 2014, 9, e109746.	2.5	2
5	Sample size determination for within-device precision. Journal of Chemometrics, 2014, 28, 202-211.	1.3	1
6	Applications of the Bayesian Prior Information to Evaluation of Equivalence of Similar Biological Medicinal Products. Journal of Biopharmaceutical Statistics, 2014, 24, 1254-1263.	0.8	5
7	An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses. Statistics in Medicine, 2014, 33, 3300-3317.	1.6	6
8	Quality of life (QOL) among community dwelling older people in Taiwan measured by the CASP-19, an index to capture QOL in old age. Archives of Gerontology and Geriatrics, 2013, 57, 143-150.	3.0	39
9	Immune gene expression profiles in swine inguinal lymph nodes with different viral loads of porcine circovirus type 2. Veterinary Microbiology, 2013, 162, 519-529.	1.9	7
10	Application of the parallel line assay to assessment of biosimilar products based on binary endpoints. Statistics in Medicine, 2013, 32, 449-461.	1.6	4
11	An Approximate Approach to Sampling Size Determination for the Equivalence Hypothesis. Journal of Biopharmaceutical Statistics, 2013, 23, 526-538.	0.8	3
12	Statistical inference on censored data for targeted clinical trials under enrichment design. Pharmaceutical Statistics, 2013, 12, 165-173.	1.3	4
13	Statistical Methods for Bridging Studies. Journal of Biopharmaceutical Statistics, 2012, 22, 903-915.	0.8	9
14	An inferential procedure for the probability of passing the USP dissolution test. Pharmaceutical Statistics, 2012, 11, 32-38.	1.3	2
15	Authors' reply to the letter to the editor by L. Chen and Y. X. Liu. Pharmaceutical Statistics, 2012, 11, 343-345.	1.3	0
16	Enrichment Design. , 2012, , 456-458.		0
17	Evaluation of Linearity in Assay Validation. , 2012, , 467-474.		0
18	Bridging Studies. , 2012, , 208-211.		0

#	Article	IF	CITATIONS
19	Predicting Healthcare Utilization Using a Pharmacy-based Metric With the WHO's Anatomic Therapeutic Chemical Algorithm. Medical Care, 2011, 49, 1031-1039.	2.4	57
20	Immunopathological characterization of porcine circovirus type 2 infection-associated follicular changes in inguinal lymph nodes using high-throughput tissue microarray. Veterinary Microbiology, 2011, 149, 72-84.	1.9	20
21	A consistency approach to evaluation of bridging studies and multi-regional trials. Statistics in Medicine, 2011, 30, 2171-2186.	1.6	13
22	An alternative phase II/III design for continuous endpoints. Pharmaceutical Statistics, 2011, 10, 105-114.	1.3	5
23	Statistical evaluation of nonâ€profile analyses for the <i>in vitro</i> bioequivalence. Journal of Chemometrics, 2010, 24, 617-625.	1.3	7
24	Proposals of statistical consideration to evaluation of results for a specific region in multiâ€regional trials – Asian perspective. Pharmaceutical Statistics, 2010, 9, 201-206.	1.3	20
25	Evaluation of Linearity in Assay Validation. , 2010, , 467-474.		0
26	Sample Size Determination for a Specific Region in a Multiregional Trial. Journal of Biopharmaceutical Statistics, 2010, 20, 870-885.	0.8	48
27	Targeted Clinical Trials. , 2010, , 22-1-22-11.		3
28	Targeted Clinical Trials. , 2010, , 1331-1337.		0
29	Therapeutic Equivalence. , 2010, , 1349-1353.		0
30	Equivalence Trials. , 2010, , 459-463.		0
31	Bridging Studies. , 2010, , 208-211.		0
32	Statistical Test for Evaluation of Biosimilarity in Variability of Follow-On Biologics. Journal of Biopharmaceutical Statistics, 2009, 20, 75-89.	0.8	13
33	Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes. Clinical Rehabilitation, 2009, 23, 64-71.	2.2	30
34	Guest Editors' Note. Journal of Biopharmaceutical Statistics, 2009, 20, 1-2.	0.8	0
35	Statistical Inference for the Within-Device Precision of Quantitative Measurements in Assay Validation. Journal of Biopharmaceutical Statistics, 2009, 19, 763-778.	0.8	5
36	Statistical methods for evaluating the linearity in assay validation. Journal of Chemometrics, 2009, 23, 56-63.	1.3	9

#	Article	IF	CITATIONS
37	Deviations from linearity in statistical evaluation of linearity in assay validation. Journal of Chemometrics, 2009, 23, 487-494.	1.3	6
38	Inference on treatment effects for targeted clinical trials under enrichment design. Pharmaceutical Statistics, 2009, 8, 356-370.	1.3	17
39	Statistical Assessment of Biosimilar Products. Journal of Biopharmaceutical Statistics, 2009, 20, 10-30.	0.8	31
40	On the exact interval estimation for the difference in paired areas under the ROC curves. Statistics in Medicine, 2008, 27, 224-242.	1.6	37
41	A nonâ€inferiority test for diagnostic accuracy based on the paired partial areas under ROC curves. Statistics in Medicine, 2008, 27, 1762-1776.	1.6	47
42	Radiographic Assessment of Skeletal Maturation Stages for Orthodontic Patients: Hand-wrist Bones or Cervical Vertebrae?. Journal of the Formosan Medical Association, 2008, 107, 316-325.	1.7	57
43	Relationship Between Age at Menarche and Skeletal Maturation Stages in Taiwanese Female Orthodontic Patients. Journal of the Formosan Medical Association, 2008, 107, 527-532.	1.7	23
44	Statistical Evaluation of Quality Performance on Genomic Composite Biomarker Classifiers. Journal of the Formosan Medical Association, 2008, 107, S28-S34.	1.7	0
45	Statistical Methods for Targeted Clinical Trials under Enrichment Design. Journal of the Formosan Medical Association, 2008, 107, S35-S42.	1.7	13
46	A Permutation Two One-Sided Tests Procedure to Detect Minimal Fold Changes of Gene Expression Levels. Journal of Biopharmaceutical Statistics, 2008, 18, 808-826.	0.8	1
47	A Two-Stage Design for Drug Screening Trials Based on Continuous Endpoints. Drug Information Journal, 2008, 42, 253-262.	0.5	5
48	Commentary on "Accounting for the Interim Safety Monitoring of an Adverse Event Upon Termination of a Clinical Trial― Journal of Biopharmaceutical Statistics, 2008, 18, 641-643.	0.8	1
49	On Statistical Evaluation of the Linearity in Assay Validation. Journal of Biopharmaceutical Statistics, 2008, 18, 677-690.	0.8	14
50	Statistical Issues on the Diagnostic Multivariate Index Assay for Targeted Clinical Trials. Journal of Biopharmaceutical Statistics, 2007, 18, 167-182.	0.8	15
51	Noninferiority Tests Based on Concordance Correlation Coefficient for Assessment of the Agreement for Gene Expression Data from Microarray Experiments. Journal of Biopharmaceutical Statistics, 2007, 17, 309-327.	0.8	10
52	Use of Prior Information for Bayesian Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2007, 17, 109-121.	0.8	30
53	Factors associated with referral compliance of abnormal immunochemical faecal occult blood test. Journal of Medical Screening, 2007, 14, 186-190.	2.3	6
54	Two-phase survey of eating disorders in gifted dance and non-dance high-school students in Taiwan. Psychological Medicine, 2007, 37, 1085-1096.	4.5	30

#	Article	IF	CITATIONS
55	Rethinking Statistical Approaches to Evaluating Drug Safety. Yonsei Medical Journal, 2007, 48, 895.	2.2	7
56	An Alternative Approach to Evaluation of Poolability for Stability Studies. Journal of Biopharmaceutical Statistics, 2006, 16, 1-14.	0.8	9
57	Effects of Exercise Training on Heart Rate Variability After Coronary Angioplasty. Physical Therapy, 2006, 86, 626-635.	2.4	38
58	Tests of equivalence and non-inferiority for diagnostic accuracy based on the paired areas under ROC curves. Statistics in Medicine, 2006, 25, 1219-1238.	1.6	46
59	Tests for Equivalence Based on Odds Ratio for Matched-Pair Design. Journal of Biopharmaceutical Statistics, 2005, 15, 889-901.	0.8	24
60	A Bayesian Noninferiority Approach to Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2004, 14, 291-300.	0.8	16
61	Bridging Bioequivalence Studies. Journal of Biopharmaceutical Statistics, 2004, 14, 857-867.	0.8	2
62	A TWO-STAGE DESIGN FOR BRIDGING STUDIES. Journal of Biopharmaceutical Statistics, 2004, 15, 75-83.	0.8	21
63	Better prediction of prognosis for patients with nasopharyngeal carcinoma using primary tumor volume. Cancer, 2004, 100, 2160-2166.	4.1	112
64	Simultaneous Non-inferiority Test of Sensitivity and Specificity for Two Diagnostic Procedures in the Presence of a Gold Standard. Biometrical Journal, 2003, 45, 47-60.	1.0	9
65	A Group Sequential Approach to Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2003, 13, 793-801.	0.8	18
66	BRIDGING STUDIES IN CLINICAL DEVELOPMENT. Journal of Biopharmaceutical Statistics, 2002, 12, 359-367.	0.8	28
67	BAYESIAN APPROACH TO EVALUATION OF BRIDGING STUDIES. Journal of Biopharmaceutical Statistics, 2002, 12, 401-408.	0.8	34
68	Sample Size Requirements for Evaluation of Bridging Evidence. Biometrical Journal, 2002, 44, 969-981.	1.0	23
69	Tests for equivalence or non-inferiority for paired binary data. Statistics in Medicine, 2002, 21, 231-245.	1.6	132
70	Unconditional Exact Tests for Equivalence or Noninferiority for Paired Binary Endpoints. Biometrics, 2001, 57, 478-483.	1.4	39
71	On difference factor in assessment of dissolution similarity. Communications in Statistics - Theory and Methods, 2000, 29, 1089-1113.	1.0	1
72	ASSESSMENT OF SIMILARITY BETWEEN DISSOLUTION PROFILES*. Journal of Biopharmaceutical Statistics, 2000, 10, 229-249.	0.8	26

#	Article	IF	CITATIONS
73	In vitro dissolution profile comparisonstatistics and analysis of the similarity factor, f2. Pharmaceutical Research, 1998, 15, 889-896.	3.5	540
74	Statistical evaluation of individual bioequivalence. Communications in Statistics - Theory and Methods, 1998, 27, 1433-1451.	1.0	5
75	Robustness of bioequivalence procedures under box-cox alternatives. Journal of Biopharmaceutical Statistics, 1997, 7, 135-155.	0.8	2
76	Meta-analysis for bioequivalence review. Journal of Biopharmaceutical Statistics, 1997, 7, 97-111.	0.8	30
77	Bias of two one-sided tests procedures in assessment of bioequivalence. Statistics in Medicine, 1995, 14, 853-861.	1.6	24
78	USE OF THE REPEATED CROSS-OVER DESIGNS IN ASSESSING BIOEQUIVALENCE. Statistics in Medicine, 1995, 14, 1067-1078.	1.6	31
79	Letter to the Editor on "Sample Size for Therapeutic Equivalence Based on Confidence Interval,―S. C. Lin, Drug Information Journal, 1995;29(1)45–50. Drug Information Journal, 1995, 29, 1063-1064.	0.5	3
80	Replicated Crossover Designs in Bioavailability and Bioequivalence Trials. Drug Information Journal, 1995, 29, 871-884.	0.5	4
81	Current Issues in Bioequivalence Trials. Drug Information Journal, 1995, 29, 795-804.	0.5	29
82	Recent Statistical Developments in Bioequivalence Trials — A Review of the FDA Guidance*. Drug Information Journal, 1994, 28, 851-864.	0.5	20
83	Evaluation of log-transformation in assessing bioequivalence. Communications in Statistics - Theory and Methods, 1994, 23, 421-434.	1.0	10
84	Statistical considerations in bioequivalence trials. Communications in Statistics - Theory and Methods, 1994, 23, 325-339.	1.0	2
85	Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability. Journal of Biopharmaceutical Statistics, 1993, 3, 85-102.	0.8	5
86	On the assessment of variability in bioavailability/bioequivalence studies. Communications in Statistics - Theory and Methods, 1992, 21, 2591-2607.	1.0	38
87	Estimation of direct formulation effect under log-normal distribution in bioavailability/bioequivalence studies. Statistics in Medicine, 1992, 11, 881-896.	1.6	17
88	Sample size determination for the two one-sided tests procedure in bioequivalence. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 101-104.	0.6	95
89	Bioequivalence and intrasubject variability. Journal of Biopharmaceutical Statistics, 1991, 1, 205-219.	0.8	26
			_

86